The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
Status:
Recruiting
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety
of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in resectable locally
advanced head and neck squamous cell carcinoma. The eligible patients are scheduled to
administered neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound
paclitaxel and cisplatin for two cycles. Radical resection will be performed in 3-4 weeks
after the first day of the second cycle. The overall primary study hypothesis is that the
novel neoadjuvant combination regime improves the pathological complete response (pCR) rate,
with tolerable side effects.